Items Tagged ‘PD-1 inhibitors’

October 27th, 2016

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing

By

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with advanced stage lung cancer still die from their disease. Precision medicine continues to impact the lives […]

View full entry

Tags: General Lung Cancer, immune response, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, nsclc, opdivo, PD-1 inhibitors, pembrolizumab, precision medicine


September 14th, 2015

Early Results of Opdivo® Combined with Yervoy® Presented at 16th World Conference on Lung Cancer

By

An early-stage study shows Opdivo® (nivolumab) treatment can be safely and effectively paired with relatively low and infrequent dosages of Yervoy® (ipilimumab) immunotherapy for patients with previously untreated lung cancer, researchers said on Monday at the 16th World Conference on Lung Cancer in Denver, CO. Lung cancer remains the leading cause of cancer-related deaths worldwide. […]

View full entry

Tags: clinical trial, CTLA4, Lung Cancer, Lung Cancer - Non-Small Cell, monoclonal antibody, News, nsclc, opdivo, PD-1 inhibitors, Recurrent Lung Cancer - Non-Small Cell, Yervoy


September 10th, 2015

Updated Trial Results Demonstrating Benefit of Opdivo® Were Released Today at the 16th World Conference on Lung Cancer

By

Results from the CheckMate -017 and -063 clinical trials evaluating Opdivo® (nivolumab) in previously treated squamous cell non-small cell lung cancer (NSCLC) were released today at the 16th World Conference on Lung Cancer (Abstract #736), and the studies showed sustained survival benefit. Both trials showed an estimated 18-month overall survival (OS) rate of 27% (CheckMate […]

View full entry

Tags: CheckMate, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, non-small cell lung cancer, nsclc, opdivo, PD-1 inhibitors, Recurrent Lung Cancer - Non-Small Cell, stage III, stage IV